350 rub
Journal Technologies of Living Systems №3 for 2012 г.
Article in number:
Immunohistochemical study of the caveolin-1 expression in esophageal squamous cell carcinoma
Keywords: esophageal carcinoma immunohistochemistry caveolin-1 prognosis
Authors:
V.V. Delektorskaya, G.Ju. Chemeris, P.V. Kononec, Ju.V. Bondarenko, I.B. Zborovskaya
Abstract:
The aim of our study was to analyze the clinical significance of the Cav-1 immunohistochemical expression in 52 esophageal squamous cell carcinomas (ESCC) and 20 adenocarcinomas of the esophagus. Increased Cav-1 immunoxpression appears to play an important role as a marker of prognosis and aggressive biological behaviour in ESCC, but not in adenocarcinoma of the esophagus. The high level of Cav-1 expression was correlated with tumor histological differentiation (р = 0,020), distant lymph node metastasis (р = 0,027) and shorter overall survival (р = 0,039) of ESCC patients. Our results indicate that the increased Cav-1 expression in ESCC is associated with tumor progression and may be useful in personalized prognosis of disease progression and future therapeutic approaches for ESCC patients.
Pages: 8-13
References
  1. Burgermeister E., Liscovitch M., Röcken C. et al. Caveats of caveolin-1 in cancer progression // Cancer Lett. 2008. V. 268. № 2. P. 187 - 201.
  2. Goetz J.G., Lajoie P., Wiseman S.M., Nabi I.R. Caveolin-1 in tumor progression: the good, the bad and the ugly // Cancer Metastasis Rev. 2008. V. 27. № 4. P. 715 - 735.
  3. Shatz M., Liscovitch M. Caveolin-1: a tumor-promoting role in human cancer // Int. J. Radiat. Biol. 2008.  V. 84. № 3. P. 177 - 189.
  4. Архипова К.А., Рыбко В.А., Землякова В.В. и др. Экспрессия кавеолина-1 в опухолях мягких тканей // Вестник РОНЦ им. Н.Н. Блохина РАМН. 2009. Т. 20. № 1. С. 4 - 9.
  5. Perrone G., Altomare V., Zagami M. et al.Caveolin-1 expression in human breast lobular cancer progression // Mod. Pathol. 2009. № 22. P. 71 - 78.
  6. Sagara Y., Mimori K., Yoshinaga K. et al.Clinical significance of Caveolin-1, Caveolin-2 and HER2/neu mRNA expression in human breast cancer // Br. J. Cancer. 2004. V. 91. № 5. P. 959 - 965.
  7. Cassoni P., Daniele L., Maldi E. et al. Caveolin-1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastases // Histopathology. 2009. V. 55. №1. P. 20 - 27.
  8. Chen H.L., Fan L.F., Gao J. et al.Differential expression and function of the caveolin-1gene in non-small cell lung carcinoma // Oncol. Rep. 2011. V. 25. № 2. P. 359 - 366.
  9. Ito Y., Yoshida H., Tomoda C. et al. Caveolin-1 and 14-3-3 sigma expression in follicular variant of thyroid  papillary carcinoma // Pathol. Res. Pract. 2005. № 201. P. 545 - 549. 
  10. Karam J.A., Lotan Y., Roehrborn C.G. et al. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence // Prostate. 2007. № 67. P. 614 - 622.
  11. Tanase C.P., Dima S., Mihai M. et al.Caveolin-1 overexpression correlates with tumour progression markers in pancreatic ductal adenocarcinoma // J. Mol. Histol. 2009. № 40. P. 2329.
  12. Waalkes S., Eggers H., Blasig H. et al.Caveolin 1 mRNA is overexpressed in malignant renal tissue and might serve as a novel diagnostic marker for renal cancer // Biomark. Med. 2011. V. 5.№ 2. P.219 - 225.
  13. Kato K., Hida Y., Miyamoto M. et al.Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage // Cancer. 2002. V. 94. №4. P. 929 - 933.
  14. Nakatani K., Wada T., Nakamura M. et al.Expression of caveolin-1 and its correlation with cisplatin sensitivity in oral squamous cell carcinoma // J. Cancer Res. Clin. Oncol. 2005. № 131. P. 44452.
  15. Van Golen K.L. Is caveolin-1 a viable therapeutic target to reduce cancer metastasis - // Expert Opin. Ther. Targets. 2006. V. 10.№ 5. P. 709 - 721.
  16. Ando T., Ishiguro H., Kimura M. et al.The overexpression of caveolin-1 and caveolin-2 correlates with a poor prognosis and tumor progression in esophageal squamous cell carcinoma // Oncol. Rep. 2007. V. 18. № 3. P. 601 - 609.